The Hyderabad-based COVID vaccine manufacturer also said that it will publish the phase 3 trial data in July and after that, it will be applying for the full licensure of COVAXIN. "It is critical to understand, and further emphasise the Phase-3 data will first be submitted to Central Drugs Standard Control Organisation (CDSCO), followed by peer-reviewed journals, with a timeline of 3 months for publication, and as communicated earlier COVAXIN phase 3 results full trial data will be made public during July. Once data from the final analysis of phase III studies are available, Bharat Biotech will apply for full licensure for COVAXIN," Bharat Biotech was quoted as saying by ANI on Wednesday.